NasdaqGM:AVDLPharmaceuticals
A Look at Avadel Pharmaceuticals’s Valuation Following New Real-World Data on LUMRYZ for Narcolepsy
If you have been keeping tabs on Avadel Pharmaceuticals (AVDL), today’s announcement may be on your radar. The company just reported fresh data on LUMRYZ for narcolepsy at the World Sleep 2025 conference, pointing to clinically significant improvements from its REFRESH real-world study. These findings not only underline LUMRYZ’s benefits for excessive daytime sleepiness and overall quality of life, they also deliver new proof that the treatment’s advantages are holding up outside of...